AC Immune Appoints Interim EVP of Development

Ticker: ACIU · Form: 6-K · Filed: Jun 11, 2025 · CIK: 1651625

Ac Immune SA 6-K Filing Summary
FieldDetail
CompanyAc Immune SA (ACIU)
Form Type6-K
Filed DateJun 11, 2025
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: personnel-change, management

TL;DR

AC Immune promotes Dr. Staffler to interim EVP of Development, overseeing immunotherapy pipeline.

AI Summary

AC Immune SA announced the appointment of Dr. Günther Staffler as interim Executive Vice President, Development, effective immediately. Dr. Staffler, who joined AC Immune in 2021, will oversee the development of the company's active immunotherapies, including clinical activities. He previously held senior R&D roles and was Chief Technical Officer at Affiris.

Why It Matters

This appointment signals a focus on advancing the company's immunotherapy pipeline, which could impact future clinical trial progress and drug development timelines.

Risk Assessment

Risk Level: low — The filing is an administrative update regarding an internal personnel change, not a financial event.

Key Players & Entities

FAQ

What is the effective date of Dr. Staffler's appointment?

The appointment is effective immediately.

What will be Dr. Staffler's primary responsibilities?

He will oversee the development of AC Immune's active immunotherapies, including clinical activities.

When did Dr. Staffler join AC Immune?

Dr. Staffler joined AC Immune in 2021.

What was Dr. Staffler's role at Affiris?

He was Chief Technical Officer at Affiris.

What is AC Immune SA's principal executive office address?

The address is EPFL Innovation Park Building B, 1015 Lausanne, Switzerland.

Filing Details

This Form 6-K (Form 6-K) was filed with the SEC on June 11, 2025 by Dr. Günther Staffler regarding AC Immune SA (ACIU).

View full filing on EDGAR

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing